U.S., April 14 -- ClinicalTrials.gov registry received information related to the study (NCT07523607) titled 'FAP PET/CT for Staging Patients With Breast Cancer' on March 09.
Brief Summary: This study aims to evaluate the clinical utility of [68Ga]Ga-FAP-2268 PET/CT for disease staging and assessment in patients with high-risk primary breast cancer. By targeting fibroblast activation protein (FAP), this novel imaging approach may offer improved tumor visualization compared to conventional imaging, which may help improve treatment planning.
Study Start Date: June 01
Study Type: INTERVENTIONAL
Condition:
Breast Cancer Detection
Intervention:
DRUG: 68Ga-FAP-2286
One scan at baseline staging, and for those reciving NACT : one scan befor...